Article

Bevacizumab appears safe for neovascular AMD in short term

The short-term clinical experience with intravitreal bevacizumab (Avastin, Genentech) supports growing perception that treatment is safe and effective for neovascular age-related macular degeneration.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
Related Content
Self-reported vision problems tied to increased sleep dysfunction in older adults
April 22nd 2025

Self-reported vision problems tied to increased sleep dysfunction in older adults

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Regeneron announces FDA issues CRL for aflibercept 8 mg (Eylea HD) sBLA
April 21st 2025

Regeneron announces FDA issues CRL for aflibercept 8 mg (Eylea HD) sBLA

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Unveiling genetic distinctions between reticular pseudodrusen and drusen
April 21st 2025

Unveiling genetic distinctions between reticular pseudodrusen and drusen

Zhaoke enrolls first patient in phase 3 trial of cyclosporine ophthalmic gel for dry eye
April 20th 2025

Zhaoke enrolls first patient in phase 3 trial of cyclosporine ophthalmic gel for dry eye

© 2025 MJH Life Sciences

All rights reserved.